There are currently 447 clinical trials in Memphis, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including St. Jude Children's Research Hospital, Saint Jude Children's Research Hospital, Baptist Memorial Hospital and Cancer Center-Memphis and University of Tennessee Health Science Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248
Recruiting
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Eye Specialty Group /ID# 252201, Memphis, Tennessee
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
NCT05611242
Recruiting
The primary objective is to establish the efficacy of intra-arterial (IA) mechanical thrombectomy (MT) with extracranial proximal carotid artery acute stenting versus non-stenting approaches in patients with acute ischemic stroke (AIS) from intracranial vessel occlusion (IVO) in the anterior circulation and have a proximal carotid occlusive disease (occlusion or severe stenosis).
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
07/09/2025
Locations: Semmes-Murphey Foundation, Memphis, Tennessee
Conditions: Acute Ischemic Stroke
Register for Updates
Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).
NCT05664113
Recruiting
The study participant is being asked to take part in this clinical trial, a type of research study, because the participant has Gastrointestinal (GI) symptoms following a Hematopoietic Cell Transplant (HCT). Primary Objective * To determine the safety and feasibility of FMT for treating a GvHD of the gut following HCT. * To determine the safety and feasibility of FMT for treating HCT induced gut dysfunction. Secondary Objectives * To assess the potential efficacy of FMT for treating a GvHD o... Read More
Gender:
ALL
Ages:
22 years and below
Trial Updated:
07/09/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Gastro-Intestinal Disorder
Register for Updates
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844
Recruiting
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Research Site, Memphis, Tennessee
Conditions: Non-small Cell Lung Cancer
Register for Updates
PARADIGM: Amplatzer Valvular Plug for PVL Closure
NCT04489823
Recruiting
The Paradigm study is a prospective, multicenter, single arm study to demonstrate the safety and effectiveness of the Amplatzer Valvular Plug III (AVP III) as a treatment for clinically significant PVLs following surgical implant of a mechanical or biological heart valve implanted in the aortic or mitral position.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Baptist Memorial Hospital, Memphis, Tennessee
Conditions: Paravalvular Aortic Regurgitation
Register for Updates
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
NCT06190717
Recruiting
This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.
Gender:
ALL
Ages:
Between 18 years and 84 years
Trial Updated:
07/08/2025
Locations: Fresenius Vascular Care Memphis MSO, Memphis, Tennessee
Conditions: Diabetes, End Stage Renal Disease
Register for Updates
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394
Recruiting
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
07/08/2025
Locations: Site Number - USA34, Memphis, Tennessee
Conditions: Dravet Syndrome
Register for Updates
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141
Recruiting
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
07/08/2025
Locations: Site Number - USA34, Memphis, Tennessee
Conditions: Developmental and Epileptic Encephalopathy
Register for Updates
Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for Surgical Wounds
NCT06750809
Recruiting
The goal of this study is to compare the cost and clinical outcomes for two temporary dressings (Allograft and PermeaDerm) used in patients that need a skin graft to heal their wound. The researchers will review cost and other treatment results including how well both temporary dressings attach to the skin, how prepared the wound bed is to receive a skin graft, how long it takes for the skin to be ready to receive a skin graft, how well the skin graft takes and any complications. Patients will f... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/08/2025
Locations: Regional One Firefighter's Burn Center, Memphis, Tennessee
Conditions: Surgical Wound, Trauma Wound, Autografts, Partial Thickness Wounds, Partial-thickness Burn
Register for Updates
Childhood Cancer Survivor Study
NCT01120353
Recruiting
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the identification and active follow-up of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age, between 1970 and 1999 and 10,000 sibling controls. This project will study children and young adults exposed to specific therapeutic mod... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Cancer
Register for Updates
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116
Recruiting
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blin... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/07/2025
Locations: Local Institution - 2148, Memphis, Tennessee
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Register for Updates
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
NCT05011383
Recruiting
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee
Conditions: Metastatic Prostate Cancer
Register for Updates